---
schema_version: "secwatch.filing_event.v1"
accession: "0001753926-24-001793"
form_type: "8-K"
ticker: "LIPO"
cik: "0001347242"
company_name: "LIPELLA PHARMACEUTICALS INC."
filed_at: "2024-11-01T23:59:59+00:00"
generated_at: "2026-05-30T06:52:20.738487+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lipella announces 1-for-8 reverse split effective Nov 7 to meet Nasdaq bid price

## Summary
- Reverse stock split ratio of 1-for-8; effective 5:00 p.m. ET on November 7, 2024.
- Common stock begins trading split-adjusted on November 8, 2024 under symbol LIPO.
- Authorized shares unchanged at 200,000,000; par value remains $0.0001 per share.
- Split intended to bring company into compliance with Nasdaq minimum bid price requirement.
- Approved by stockholders at Annual Meeting on September 10, 2024; CUSIP changes to 53630L209.

## SEC filing metadata
- accession: 0001753926-24-001793
- form_type: 8-K
- ticker: LIPO
- cik: 0001347242
- company_name: LIPELLA PHARMACEUTICALS INC.
- filed_at: 2024-11-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1347242/000175392624001793/0001753926-24-001793-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1347242/000175392624001793/g084523_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001753926-24-001793
- JSON: https://secwatch.observer/filing/0001753926-24-001793.json
- Plain text: https://secwatch.observer/filing/0001753926-24-001793.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.